Trial site
Fujita Health University Hospital
Toyoake-shi, Aichi-ken 470-1192, JapanNot linked to an institution yet
- 18running trials
- 4closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 1/22 trials
- Phase 2/32 trials
- Phase 11 trial
- Phase 21 trial
- Status
- Recruiting10 trials
- Active, not recruiting7 trials
- Completed3 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Biogen4 trials
- Amgen3 trials
- Boehringer Ingelheim3 trials
- Daiichi Sankyo3 trials
- Takeda3 trials
- and 6 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Contact: Naotake Tsuboi (principal investigator)
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Contact: US Biogen Clinical Trial Center
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Active, not recruiting
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622· Phase 3· H. Lundbeck A/S· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
NCT05352919· Phase 3· Biogen· Source
Active, not recruiting
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567· Phase 3· Biogen· Source
Recruiting
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157· Novartis Pharmaceuticals· Source
Contact: Novartis Gene Therapies
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527· Phase 3· Japanese Gynecologic Oncology Group· Source
Contact: Takuma Fujii
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error